Proteins > cGMP-inhibited 3',5'-cyclic phosphodiesterase A
Page last updated: 2024-08-07 17:07:21
cGMP-inhibited 3',5'-cyclic phosphodiesterase A
A cGMP-inhibited 3,5-cyclic phosphodiesterase 3A that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q14432]
Synonyms
EC 3.1.4.17;
Cyclic GMP-inhibited phosphodiesterase A;
CGI-PDE A
Research
Bioassay Publications (86)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 18 (20.93) | 18.7374 |
| 1990's | 19 (22.09) | 18.2507 |
| 2000's | 26 (30.23) | 29.6817 |
| 2010's | 20 (23.26) | 24.3611 |
| 2020's | 3 (3.49) | 2.80 |
Compounds (62)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| my 5445 | Homo sapiens (human) | Ki | 16.0000 | 1 | 1 |
| theophylline | Homo sapiens (human) | IC50 | 300.0000 | 2 | 2 |
| cilostamide | Homo sapiens (human) | IC50 | 12.5316 | 6 | 8 |
| cilostamide | Homo sapiens (human) | Ki | 0.0125 | 2 | 2 |
| cilostazol | Homo sapiens (human) | IC50 | 0.3285 | 4 | 4 |
| dipyridamole | Homo sapiens (human) | IC50 | 12.7250 | 2 | 4 |
| 9-(2-hydroxy-3-nonyl)adenine | Homo sapiens (human) | IC50 | 66.9333 | 1 | 3 |
| etazolate | Homo sapiens (human) | Ki | 12.0000 | 1 | 1 |
| ibudilast | Homo sapiens (human) | IC50 | 299.0000 | 1 | 1 |
| amrinone | Homo sapiens (human) | IC50 | 52.8750 | 8 | 8 |
| 1-methyl-3-isobutylxanthine | Homo sapiens (human) | IC50 | 37.5000 | 2 | 2 |
| losartan | Homo sapiens (human) | IC50 | 13.0000 | 1 | 1 |
| 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| milrinone | Homo sapiens (human) | IC50 | 5.8848 | 27 | 29 |
| milrinone | Homo sapiens (human) | Ki | 0.1500 | 1 | 1 |
| papaverine | Homo sapiens (human) | IC50 | 5.5576 | 5 | 5 |
| papaverine | Homo sapiens (human) | Ki | 0.2480 | 2 | 4 |
| pentoxifylline | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| proxyphylline | Homo sapiens (human) | Ki | 1,000.0000 | 1 | 1 |
| 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | Homo sapiens (human) | IC50 | 300.0000 | 1 | 1 |
| rolipram | Homo sapiens (human) | IC50 | 122.0000 | 11 | 12 |
| rolipram | Homo sapiens (human) | Ki | 200.0000 | 1 | 1 |
| sulmazole | Homo sapiens (human) | IC50 | 383.3333 | 3 | 3 |
| trequinsin | Homo sapiens (human) | IC50 | 1.9502 | 1 | 2 |
| vesnarinone | Homo sapiens (human) | IC50 | 9.3700 | 3 | 3 |
| zardaverine | Homo sapiens (human) | IC50 | 14.7068 | 5 | 7 |
| 9-benzyladenine | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| eg 626 | Homo sapiens (human) | Ki | 1.4000 | 1 | 1 |
| enoximone | Homo sapiens (human) | IC50 | 11.4500 | 4 | 4 |
| piroximone | Homo sapiens (human) | IC50 | 39.0667 | 3 | 3 |
| 2-(2-methoxy-4-(methylsulfinyl)phenyl)-1h-imidazo(4,5-c)pyridine | Homo sapiens (human) | IC50 | 42.0000 | 1 | 1 |
| imazodan | Homo sapiens (human) | IC50 | 16.1182 | 11 | 11 |
| nitraquazone | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| tadalafil | Homo sapiens (human) | IC50 | 10.0000 | 3 | 3 |
| y 590 | Homo sapiens (human) | IC50 | 0.1100 | 2 | 2 |
| 9-(2-hydroxy-3-nonyl)adenine | Homo sapiens (human) | Ki | 200.0000 | 1 | 1 |
| 9-(2-hydroxy-3-nonyl)adenine | Homo sapiens (human) | IC50 | 16.0000 | 1 | 1 |
| cilomilast | Homo sapiens (human) | IC50 | 7.7208 | 3 | 3 |
| 8-methoxymethyl-3-isobutyl-1-methylxanthine | Homo sapiens (human) | IC50 | 240.0000 | 1 | 1 |
| vinpocetine | Homo sapiens (human) | IC50 | 300.0000 | 1 | 1 |
| rolipram | Homo sapiens (human) | IC50 | 3.1623 | 1 | 1 |
| roflumilast | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone | Homo sapiens (human) | IC50 | 0.5500 | 8 | 8 |
| indolidan | Homo sapiens (human) | IC50 | 3.5400 | 2 | 2 |
| bemoradan | Homo sapiens (human) | IC50 | 0.3000 | 2 | 2 |
| 1,3-dihydro-7,8-dimethyl-2h-imidazo(4,5-b)quinolin-2-one | Homo sapiens (human) | IC50 | 0.0110 | 3 | 3 |
| ci 1044 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| t 1032 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| losartan potassium | Homo sapiens (human) | IC50 | 13.0000 | 1 | 1 |
| pf 04217903 | Homo sapiens (human) | IC50 | 5.6500 | 2 | 2 |
| 3-(2,5-dimethoxyphenyl)-6-(3,4-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine | Homo sapiens (human) | IC50 | 1.7000 | 1 | 1 |
| pf-04418948 | Homo sapiens (human) | IC50 | 3.5000 | 1 | 0 |
| nitd 609 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| an2728 | Homo sapiens (human) | IC50 | 32,003.2000 | 2 | 2 |
| cc-115 | Homo sapiens (human) | IC50 | 0.6300 | 1 | 1 |
| chf6001 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| cyclic gmp | Homo sapiens (human) | IC50 | 2.4000 | 1 | 1 |
| sildenafil | Homo sapiens (human) | IC50 | 16.3419 | 11 | 12 |
| zaprinast | Homo sapiens (human) | IC50 | 391.0000 | 2 | 2 |
| vardenafil | Homo sapiens (human) | IC50 | 1.3400 | 2 | 2 |
| Imidazosagatriazinone | Homo sapiens (human) | IC50 | 0.5000 | 1 | 1 |
| bl 4162a | Homo sapiens (human) | IC50 | 0.2327 | 6 | 6 |
| 1,5-dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3h)-one | Homo sapiens (human) | IC50 | 0.1500 | 1 | 1 |
| quazinone | Homo sapiens (human) | IC50 | 0.2400 | 1 | 1 |
| lixazinone | Homo sapiens (human) | IC50 | 0.0083 | 4 | 4 |
| 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2h-pyran-4-yl)-1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidin-4-one | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| rolipram | Homo sapiens (human) | Log IC50 | 0.0040 | 1 | 1 |
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Discovery of new inhibitor for PDE3 by virtual screening.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 21, Issue:6, 2011
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.Journal of medicinal chemistry, , May-19, Volume: 48, Issue:10, 2005
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).Bioorganic & medicinal chemistry letters, , Jun-07, Volume: 14, Issue:11, 2004
Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors.Bioorganic & medicinal chemistry letters, , Nov-17, Volume: 13, Issue:22, 2003
Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.Journal of medicinal chemistry, , Volume: 30, Issue:2, 1987
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
The synthesis and biological evaluation of nucleobases/tetrazole hybrid compounds: A new class of phosphodiesterase type 3 (PDE3) inhibitors.Bioorganic & medicinal chemistry, , 06-15, Volume: 28, Issue:12, 2020
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009
Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phospJournal of medicinal chemistry, , Jun-14, Volume: 50, Issue:12, 2007
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for tJournal of medicinal chemistry, , Volume: 32, Issue:2, 1989
Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.Journal of medicinal chemistry, , Volume: 30, Issue:8, 1987
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlJournal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone.Journal of medicinal chemistry, , Volume: 29, Issue:5, 1986
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.Journal of medicinal chemistry, , Volume: 27, Issue:9, 1984
Synthesis and biological evaluation of 8-aryl-2-morpholino-7-O-substituted benzo[e][1,3]oxazin-4-ones against DNA-PK, PI3K, PDE3A enzymes and platelet aggregation.Bioorganic & medicinal chemistry, , 10-15, Volume: 25, Issue:20, 2017
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.European journal of medicinal chemistry, , Jan-01, Volume: 209, 2021
Synthesis and evaluation of novel 2-pyridone derivatives as inhibitors of phosphodiesterase3 (PDE3): a target for heart failure and platelet aggregation.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 22, Issue:18, 2012
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors.Bioorganic & medicinal chemistry, , Aug-15, Volume: 17, Issue:16, 2009
Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phospJournal of medicinal chemistry, , Jun-14, Volume: 50, Issue:12, 2007
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.Journal of medicinal chemistry, , May-19, Volume: 48, Issue:10, 2005
PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues.Bioorganic & medicinal chemistry letters, , Jun-07, Volume: 14, Issue:11, 2004
Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors.Bioorganic & medicinal chemistry letters, , Nov-17, Volume: 13, Issue:22, 2003
Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.Journal of medicinal chemistry, , Oct-08, Volume: 41, Issue:21, 1998
Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.Journal of medicinal chemistry, , May-09, Volume: 40, Issue:10, 1997
Studies of cardiotonic agents. 8. Synthesis and biological activities of optically active 6-(4-(benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)- pyridazinone (KF15232).Journal of medicinal chemistry, , Jan-05, Volume: 39, Issue:1, 1996
Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.Journal of medicinal chemistry, , May-14, Volume: 36, Issue:10, 1993
Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones.Journal of medicinal chemistry, , Dec-25, Volume: 35, Issue:26, 1992
6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents.Journal of medicinal chemistry, , Volume: 33, Issue:1, 1990
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for tJournal of medicinal chemistry, , Volume: 32, Issue:2, 1989
Cardiotonic agents. 1-Methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3 (2H)-isoquinolinones and related compounds. Synthesis and activity.Journal of medicinal chemistry, , Volume: 32, Issue:2, 1989
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.Journal of medicinal chemistry, , Volume: 31, Issue:11, 1988
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlJournal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cardiotonic agents. 5. 1,2-Dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-6-methyl-2-oxo-3- pyridinecarbonitriles and related compounds. Synthesis and inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:6, 1987
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).Journal of medicinal chemistry, , Volume: 30, Issue:2, 1987
Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone.Journal of medicinal chemistry, , Volume: 29, Issue:5, 1986
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.Journal of medicinal chemistry, , Volume: 27, Issue:9, 1984
New analgesic drugs derived from phencyclidine.Journal of medicinal chemistry, , Volume: 24, Issue:5, 1981
Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.Bioorganic & medicinal chemistry, , 08-01, Volume: 27, Issue:15, 2019
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Current landscape of phosphodiesterase 10A (PDE10A) inhibition.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.European journal of medicinal chemistry, , Volume: 46, Issue:9, 2011
Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.Journal of medicinal chemistry, , Jan-25, Volume: 50, Issue:2, 2007
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.Bioorganic & medicinal chemistry letters, , Volume: 16, Issue:3, 2006
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 15, Issue:7, 2005
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).Bioorganic & medicinal chemistry letters, , Jun-07, Volume: 14, Issue:11, 2004
Synthesis and biological evaluation of 2,5-dihydropyrazol.Bioorganic & medicinal chemistry letters, , Dec-04, Volume: 10, Issue:23, 2000
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.Journal of medicinal chemistry, , Dec-14, Volume: 43, Issue:25, 2000
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.Journal of medicinal chemistry, , Feb-24, Volume: 43, Issue:4, 2000
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.Journal of medicinal chemistry, , Mar-25, Volume: 42, Issue:6, 1999
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Nov-17, Volume: 8, Issue:22, 1998
Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.Journal of medicinal chemistry, , Oct-08, Volume: 41, Issue:21, 1998
Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.Journal of medicinal chemistry, , May-09, Volume: 40, Issue:10, 1997
9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.Journal of medicinal chemistry, , Jun-06, Volume: 40, Issue:12, 1997
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.Journal of medicinal chemistry, , Jul-05, Volume: 39, Issue:14, 1996
Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.Journal of medicinal chemistry, , May-14, Volume: 36, Issue:10, 1993
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.Journal of medicinal chemistry, , Volume: 27, Issue:9, 1984
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.Bioorganic & medicinal chemistry, , Sep-15, Volume: 23, Issue:18, 2015
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.Bioorganic & medicinal chemistry, , Jan-15, Volume: 18, Issue:2, 2010
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).Journal of medicinal chemistry, , Volume: 30, Issue:2, 1987
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.Journal of medicinal chemistry, , Sep-25, Volume: 51, Issue:18, 2008
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).Bioorganic & medicinal chemistry letters, , Jun-07, Volume: 14, Issue:11, 2004
Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.Journal of medicinal chemistry, , May-08, Volume: 46, Issue:10, 2003
Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.Journal of medicinal chemistry, , Aug-02, Volume: 44, Issue:16, 2001
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).Journal of medicinal chemistry, , Volume: 30, Issue:2, 1987
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.Journal of medicinal chemistry, , Volume: 27, Issue:9, 1984
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.Journal of medicinal chemistry, , Volume: 31, Issue:11, 1988
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.Journal of medicinal chemistry, , May-14, Volume: 36, Issue:10, 1993
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.Journal of medicinal chemistry, , Feb-21, Volume: 35, Issue:4, 1992
6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents.Journal of medicinal chemistry, , Volume: 33, Issue:1, 1990
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for tJournal of medicinal chemistry, , Volume: 32, Issue:2, 1989
Chemistry and positive inotropic effect of pelrinone and related derivatives. A novel class of 2-methylpyrimidones as inotropic agents.Journal of medicinal chemistry, , Volume: 31, Issue:4, 1988
Cardiotonic agents. 6. Synthesis and inotropic activity of 2,4-dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-3H-pyrazol-3-ones: ring-contracted analogues of imazodan (CI-914).Journal of medicinal chemistry, , Volume: 30, Issue:10, 1987
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlJournal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cardiotonic agents. 3. Synthesis and biological activity of novel 6-(substituted 1H-imidazol-4(5)-yl)-3(2H)-pyridazinones.Journal of medicinal chemistry, , Volume: 29, Issue:2, 1986
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.Journal of medicinal chemistry, , Volume: 27, Issue:9, 1984
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.Journal of medicinal chemistry, , 05-23, Volume: 62, Issue:10, 2019
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Volume: 60, 2013
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.Bioorganic & medicinal chemistry letters, , May-02, Volume: 15, Issue:9, 2005
Heteroatom analogues of bemoradan: chemistry and cardiotonic activity of 1,4-benzothiazinylpyridazinones.Journal of medicinal chemistry, , Volume: 35, Issue:1, 1992
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.Journal of medicinal chemistry, , May-08, Volume: 46, Issue:10, 2003
Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.Bioorganic & medicinal chemistry letters, , Jan-21, Volume: 12, Issue:2, 2002
Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.Journal of medicinal chemistry, , Aug-02, Volume: 44, Issue:16, 2001
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for tJournal of medicinal chemistry, , Volume: 32, Issue:2, 1989
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.Journal of medicinal chemistry, , Volume: 31, Issue:11, 1988
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlJournal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).Journal of medicinal chemistry, , Volume: 30, Issue:2, 1987
Cardiotonic agents. 4. Synthesis and biological evaluation of N-substituted 2,4,4a,5-tetrahydro-3H-indeno[1,2-c]pyridazin-3-ones: rigid structures derived from CI-930 and analogues.Journal of medicinal chemistry, , Volume: 29, Issue:11, 1986
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.Journal of medicinal chemistry, , Volume: 27, Issue:9, 1984
Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.Journal of medicinal chemistry, , May-14, Volume: 36, Issue:10, 1993
6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents.Journal of medicinal chemistry, , Volume: 33, Issue:1, 1990
Heteroatom analogues of bemoradan: chemistry and cardiotonic activity of 1,4-benzothiazinylpyridazinones.Journal of medicinal chemistry, , Volume: 35, Issue:1, 1992
6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents.Journal of medicinal chemistry, , Volume: 33, Issue:1, 1990
Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.Journal of medicinal chemistry, , Jul-10, Volume: 35, Issue:14, 1992
Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility.Journal of medicinal chemistry, , Jul-10, Volume: 35, Issue:14, 1992
1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation.Journal of medicinal chemistry, , Volume: 34, Issue:9, 1991
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.Journal of medicinal chemistry, , Dec-14, Volume: 43, Issue:25, 2000
Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.European journal of medicinal chemistry, , Mar-05, Volume: 213, 2021
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.Journal of medicinal chemistry, , 05-23, Volume: 62, Issue:10, 2019
Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.Bioorganic & medicinal chemistry, , May-01, Volume: 23, Issue:9, 2015
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Volume: 60, 2013
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 15, Issue:7, 2005
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.Bioorganic & medicinal chemistry letters, , May-02, Volume: 15, Issue:9, 2005
Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5(')-sulfonamide moiety of phenyl ring.Bioorganic & medicinal chemistry letters, , May-03, Volume: 14, Issue:9, 2004
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).Bioorganic & medicinal chemistry letters, , Jun-07, Volume: 14, Issue:11, 2004
1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.Bioorganic & medicinal chemistry letters, , Jul-21, Volume: 13, Issue:14, 2003
Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.Journal of medicinal chemistry, , Jun-21, Volume: 44, Issue:13, 2001
Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.Journal of medicinal chemistry, , Jul-04, Volume: 40, Issue:14, 1997
Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.Journal of medicinal chemistry, , Jul-10, Volume: 35, Issue:14, 1992
Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility.Journal of medicinal chemistry, , Jul-10, Volume: 35, Issue:14, 1992
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.Journal of medicinal chemistry, , Feb-21, Volume: 35, Issue:4, 1992
1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation.Journal of medicinal chemistry, , Volume: 34, Issue:9, 1991
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.Journal of medicinal chemistry, , Volume: 31, Issue:11, 1988
Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.Journal of medicinal chemistry, , Volume: 30, Issue:2, 1987
Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.Journal of medicinal chemistry, , Jul-10, Volume: 35, Issue:14, 1992
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.Journal of medicinal chemistry, , Volume: 31, Issue:11, 1988
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).Journal of medicinal chemistry, , Volume: 30, Issue:2, 1987
Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.Journal of medicinal chemistry, , Volume: 30, Issue:2, 1987
Enables
This protein enables 8 target(s):
| Target | Category | Definition |
|---|
| 3',5'-cyclic-nucleotide phosphodiesterase activity | molecular function | Catalysis of the reaction: a nucleoside 3',5'-cyclic phosphate + H2O = a nucleoside 5'-phosphate. [RHEA:14653] |
| 3',5'-cyclic-AMP phosphodiesterase activity | molecular function | Catalysis of the reaction: 3',5'-cyclic AMP + H2O = AMP + H+. [GOC:ai, RHEA:25277] |
| cGMP-inhibited cyclic-nucleotide phosphodiesterase activity | molecular function | Catalysis of the reaction: nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate; catalytic activity is decreased in the presence of cGMP. [GOC:mah] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| nuclear estrogen receptor activity | molecular function | Combining with estrogen and transmitting the signal within the cell to trigger a change in cell activity or function. [GOC:signaling, PMID:17615392] |
| metal ion binding | molecular function | Binding to a metal ion. [GOC:ai] |
| 3',5'-cyclic-GMP phosphodiesterase activity | molecular function | Catalysis of the reaction: 3',5'-cyclic GMP + H2O = GMP + H+. [RHEA:16957] |
| estrogen binding | molecular function | Binding to an estrogen. [GOC:dos] |
Located In
This protein is located in 2 target(s):
| Target | Category | Definition |
|---|
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
| membrane | cellular component | A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it. [GOC:dos, GOC:mah, ISBN:0815316194] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
Involved In
This protein is involved in 18 target(s):
| Target | Category | Definition |
|---|
| oocyte maturation | biological process | A developmental process, independent of morphogenetic (shape) change, that is required for an oocyte to attain its fully functional state. Oocyte maturation commences after reinitiation of meiosis commonly starting with germinal vesicle breakdown, and continues up to the second meiotic arrest prior to fertilization. [GOC:devbiol, https://www.ncbi.nlm.nih.gov/books/NBK279054/] |
| lipid metabolic process | biological process | The chemical reactions and pathways involving lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. Includes fatty acids; neutral fats, other fatty-acid esters, and soaps; long-chain (fatty) alcohols and waxes; sphingoids and other long-chain bases; glycolipids, phospholipids and sphingolipids; and carotenes, polyprenols, sterols, terpenes and other isoprenoids. [GOC:ma] |
| G protein-coupled receptor signaling pathway | biological process | The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane. [GOC:bf, GOC:mah, PMID:16902576, PMID:24568158, Wikipedia:G_protein-coupled_receptor] |
| response to xenobiotic stimulus | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
| cAMP-mediated signaling | biological process | An intracellular signaling cassette that starts with production of cyclic AMP (cAMP), and ends with activation of downstream effectors that further transmit the signal within the cell. [GOC:signaling] |
| cGMP-mediated signaling | biological process | An intracellular signaling cassette that starts with production of cyclic GMP (cGMP), and ends with activation of downstream effectors that further transmit the signal within the cell. [GOC:signaling] |
| regulation of meiotic nuclear division | biological process | Any process that modulates the frequency, rate or extent of meiotic nuclear division, the process in which the nucleus of a diploid cell divides twice forming four haploid cells, one or more of which usually function as gametes. [GOC:ems, GOC:ma] |
| negative regulation of apoptotic process | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. [GOC:jl, GOC:mtg_apoptosis] |
| negative regulation of vascular permeability | biological process | Any process that reduces the extent to which blood vessels can be pervaded by fluid. [GOC:jl] |
| positive regulation of vascular permeability | biological process | Any process that increases the extent to which blood vessels can be pervaded by fluid. [GOC:jl] |
| steroid hormone mediated signaling pathway | biological process | The series of molecular signals mediated by a steroid hormone binding to a receptor. [PMID:12606724] |
| negative regulation of cAMP-mediated signaling | biological process | Any process which stops, prevents, or reduces the frequency, rate or extent of cAMP-mediated signaling. [GOC:jl] |
| positive regulation of oocyte development | biological process | Any process that increases the rate or extent of the process whose specific outcome is the progression of an oocyte over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell. [GOC:dph, GOC:tb] |
| regulation of ribonuclease activity | biological process | Any process that modulates the rate, frequency, or extent of ribonuclease activity, catalysis of the hydrolysis of phosphodiester bonds in chains of RNA. [GOC:dph, GOC:tb] |
| cellular response to cGMP | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cGMP (cyclic GMP, guanosine 3',5'-cyclophosphate) stimulus. [GOC:mah] |
| cellular response to transforming growth factor beta stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a transforming growth factor beta stimulus. [GOC:ecd, PMID:15451575] |
| apoptotic signaling pathway | biological process | The series of molecular signals which triggers the apoptotic death of a cell. The pathway starts with reception of a signal, and ends when the execution phase of apoptosis is triggered. [GOC:mtg_apoptosis] |
| negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of an adenylate cyclase-activating G protein-coupled receptor signaling pathway. [GOC:hjd, PMID:19246489] |